




















The German Standing Committee on 
Vaccination (STIKO) recommends annu-
al vaccination against seasonal influen-
za for the following target groups: people 
aged 60 years and over; pregnant wom-
en; children, adolescents and adults with 
an increased risk for severe influenza re-
sulting from an underlying disease; res-
idents of nursing homes; persons at in-
creased risk of exposure or who may act 
as a possible source of infection for indi-
viduals at particular risk under their care 
(e.g. medical personnel) [1]. The recom-
mendation is aimed at preventing severe 
illness and death from influenza in these 
target groups. STIKO does not currently 
recommend universal influenza vaccina-
tion of healthy children and adolescents.
Until September 2012, only trivalent 
inactivated influenza vaccines (TIV) were 
available in Germany, including non-ad-
juvanted and adjuvanted vaccines from 
several manufacturers [2]. To date, STIKO 
has recommended annual vaccination 
with a seasonal influenza vaccine “con-
taining the antigen combination currently 
endorsed by WHO”, without specification 
of vaccine type. In 2011, a trivalent live-at-
tenuated influenza vaccine (LAIV) was li-
censed in the European Union (EU) for 
children and adolescents aged 2–17 years; 
however, it was not available in Germa-
ny until 2012. STIKO evaluated the need 
for a vaccine-type-specific recommenda-
tion for this age group, following its stan-
dard operating procedure for the develop-
ment of evidence-based vaccination rec-
ommendations (SOP) [3]. Since this was 
not a completely new recommendation 
but an adaptation of the existing recom-
mendation of seasonal influenza vaccina-
tion, only the pertinent items of the SOP 
have been addressed.
Data on efficacy, safety, and reactoge-
nicity of LAIV is available from random-
ized placebo-controlled trials and from 
randomized comparative trials with inac-
tivated influenza vaccines. In six placebo- 
controlled trials, efficacy of trivalent 
LAIV against laboratory-confirmed in-
fluenza in children aged 6–71 months was 
investigated. Pooled analysis of these stud-
ies showed 77% [95% confidence interval 
(CI): 72–80%] efficacy of LAIV against 
influenza illness caused by antigenical-
ly matched viruses [4]. In addition, effi-
cacy, safety, and reactogenicity of LAIV 
in children and adolescents were directly 
compared to non-adjuvanted TIV in three 
randomized trials, so-called head-to-head 
studies.
The epidemiological and virological 
characteristics of influenza virus infec-
tions show large variations with respect 
to season and geographic region. Hence, 
placebo-controlled studies using either 
LAIV or TIV performed in different pop-
ulations, in different seasons, and with 
variable study designs are of limited val-
ue for the comparative evaluation of LAIV 
vs. TIV. Therefore, STIKO based its evalu-
ation on data from the three head-to-head 
studies in the age group 2–17 years.
The vaccine
Trivalent Fluenz® (produced by Astra-
Zeneca) was introduced in September 
2012 as the only LAIV available in Ger-
many. The identical vaccine was licensed 







2003 under the brand name FluMist®. In 
the US, but not yet in the EU, trivalent 
LAIV has since been replaced by a quad-
rivalent formulation. In contrast to TIV, 
which is administered by injection, LAIV 
has the advantage of nasal application, 
which may improve acceptance of the an-
nual influenza vaccination among chil-
dren and their parents.
The vaccine contains reassortants of 
the cold-adapted ‘Ann Arbor’ attenuat-
ed influenza virus strain, whose genes 
encoding for hemagglutinin (HA) and 
 neuraminidase (NA) are replaced by the 
corresponding genes of the respective 
recommended seasonal influenza virus 
strains. After nasal application, the vac-
cine viruses multiply mostly in the upper 
airways, but—owing to cold adaptation—
only to a limited extent in the warmer low-
er airways. LAIV induces both a systemic 
and local mucosal immune response [5].
With respect to contraindications, the 
European summary of product character-
istics (SPC) of Fluenz® [6] differs from the 
prescribing information of FluMist® in the 
US [7]. While the US prescribing informa-
tion discourages the use of LAIV in per-
sons with any form of asthma or history 
of recurrent wheezing, this applies only 
to persons with severe asthma or current 
wheezing in the European SPC. Because 
Fluenz® contains live virus, it must not be 
used in persons with immunodeficiency 
or immunosuppression, but may be used 
in persons who are treated with inhalative 
or low dose systemic steroids. As vaccinat-
ed persons may excrete the vaccine virus, 
they should avoid close contact with se-
verely immunocompromised persons for 
1–2 weeks. Further contraindications in-
clude allergies to chicken egg protein or 
other vaccine components and concom-
itant treatment with salicylic acid due to 
the theoretical risk of Reye’s syndrome.
Methods
We performed a systematic literature 
search for studies comparing efficacy and 
safety of LAIV and TIV. We searched the 
databases PubMed, Embase, Cochrane 
Central Register of Controlled Trials, and 
Cochrane Database of Systematic Re-
views using the search string [influenza 
AND live AND (vaccine* OR immuniz*) 
AND (efficacy OR effectiveness)]. The re-
sulting list of articles was independently 
screened for relevance by authors GF and 
TH, first by title, then by abstract and fi-
nally by full text (. Fig. 1). References of 
articles identified by this procedure were 
checked for additional relevant publica-
tions. Inclusion criteria were: randomized 
or observational studies including partici-
pants aged 2–17 years; immunization with 
trivalent LAIV based on Ann Arbor strain 
virus (intervention group) and TIV (com-
parison group); reporting of one or more 
of the outcomes rated as ‘critical’ or ‘im-
portant’ by the STIKO working group on 
influenza (see . Tab. 2).
We identified two randomized head-
to-head studies comparing LAIV and TIV 
in children aged ≤6 years and one study 
in 6- to 17-year-olds (. Tab. 1). Further-
more, we identified one observation-
al study in children aged 5–18 years [8], 
which we excluded from further analy-
sis because study participants in the in-
tervention group differed substantially in 
baseline risk for influenza from those in 
the comparison group (healthy children 
were vaccinated with LAIV, children with 
increased risk of influenza due to an un-
derlying chronic condition were vaccinat-
ed with TIV). In addition, we found five 
publications with meta-analyses and/or 
subgroup analyses of efficacy and safety 
data from these three studies and place-
bo-controlled studies of LAIV [4, 9, 10, 11, 
12], which we additionally considered in 
the evidence appraisal process.
We applied the framework proposed 
by the Grading of Recommendations 
Assessment, Development and Evalua-
tion (GRADE) working group (http://
www.gradeworkinggroup.org) to eval-
uate the quality of the evidence for effi-
cacy and safety of LAIV relative to TIV. 
The main question was whether chil-
dren aged 2–17 years with an indication 
for seasonal influenza vaccination (popu-
lation) should preferentially be vaccinat-
ed with LAIV (intervention) in compar-
ison to TIV (comparison) by considering 
various clinical endpoints related to effi-
cacy and safety (outcomes). The STIKO 
working group on influenza ranked out-
comes as ‘critical’ or ‘important’ regard-
ing decision-making (. Tab. 2). We ex-
tracted data on these outcomes from the 
three randomized head-to-head stud-
ies of LAIV and TIV in children and ad-
olescents. We performed a meta-analysis 
(random-effects model) of the data from 
the two studies in children <6 years of age, 
but analyzed the study of older children 
separately because of the heterogenous 
study populations. We rated the quality of 
the evidence according to GRADE crite-




Two of the three identified head-to-head 
studies included approximately 10,500 
children aged 6–71 months [13] and 
6–59 months [14], respectively. In these 
studies, LAIV was 51% (95% CI: 24%–
68%) and 54% (95% CI: 45%–62%) more 
effective against laboratory-confirmed in-
fluenza than TIV (. Fig. 2a).
589 articles potentially eligible 
149 abstracts screened
5 articles screened as full text
3 studies included
440 irrelevant articles excluded
144 irrelevant articles excluded










The pooled relative efficacy of LAIV 
against hospitalization due to any cause 
was 11% (95% CI: −16%–32%), i.e. LAIV 
was slightly, but not statistically signifi-
cantly more effective than TIV. The end-
point lower respiratory tract illness (LR-
TI) was only reported by Belshe et al. [14] 
with a relative efficacy of LAIV of 45% 
(95% CI: 3%–69%). No deaths were re-
ported in either study.
These analyses included children un-
der 2 years of age, for whom LAIV was 
ultimately not licensed due to safety con-
cerns. In a meta-analysis [12] of data from 
these two studies restricted to children 
aged 2–6 years, the pooled estimate of the 
relative efficacy of LAIV vs. TIV against 
laboratory-confirmed influenza was 53% 
(95% CI: 42%–62%), based on 368 influ-
enza cases among nearly 5800 children. 
Other endpoints were not reported in that 
particular publication.
Children aged 6–17 years
For the age group 6–17 years, the on-
ly available data are those from the study 
by Fleming et al. [15], which included ap-
proximately 2200 children with a clinical 
diagnosis of asthma. In this study, LAIV 
was 32% (95% CI: 3%–52%) more effec-
tive against laboratory-confirmed influ-
enza than TIV (. Fig. 2b). Age-strati-
fied data from this study were published 
by Belshe et al. [9], showing similar rel-
ative efficacy of LAIV vs. TIV in the age 
groups 6–11 years (31%; 95% CI: −8%–
57%; 1376 subjects) and 12–17 years 
(30%; 95%CI: −43%–66%; 835 subjects), 
both of which, however, were not statisti-
cally significant. Incidences of LRTI were 
not reported. Hospitalizations were rare 
(only two cases) and no deaths occurred.
Safety and reactogenicity
Safety endpoints ranked as critical or im-
portant by STIKO (see . Tab. 2) are re-
ported in different ways in the three pub-
lications.
Belshe et al. [14], whose study includ-
ed children aged 6–59 months, report 
medically significant wheezing (MSW) 
within 42 days of vaccination. They ob-
served a significantly higher rate of MSW 
in previously unvaccinated children aged 
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than after vaccination with TIV [risk ratio 
(RR)=1.60, 95% CI: 1.05–2.44), while rates 
were similar for children ≥24 months. In 
addition, MSW and hospitalization with-
in 180 days of vaccination are reported. 
LAIV-vaccinated children <12 months 
were hospitalized significantly more of-
ten in the 180 days after vaccination than 
TIV-vaccinated children (RR=2.33, 95% 
CI: 1.36–4.01). Incidences of the other 
safety endpoints of interest (LRTI), un-
scheduled health care visit, any wheez-
ing, fever >39.5°C, myalgia/arthralgia] are 
not reported. One death occurred in each 
vaccine group—one due to aspiration of a 
foreign body and one due to a house fire.
Ashkenazi et al. [13], whose study in-
cluded children aged 6–71 months, re-
port the occurrence of fever, myalgia, 
and wheezing within 11 days of vaccina-
tion. In addition, wheezing in the peri-
od 11–41 days after vaccination is report-
ed. Rates of these events were similar after 
vaccination with LAIV or TIV. No num-
bers are reported for the endpoints MSW 
and LRTI; it is only stated in the text that 
there was no difference in the incidence of 
bronchospasm, dyspnea, pneumonia, or 
LRTI. Incidences of hospitalizations and 
unscheduled health care visits are only re-
ported as efficacy endpoints over the en-
tire influenza season, making it impos-
sible to judge whether they occurred in 
temporal relation to vaccination. No par-
ticipants died during the study.
Ambrose et al. [16] analyzed safety da-
ta for the subgroup of 1940 children aged 
24–71 months with asthma or a history 
of wheezing who had been included in 
these two studies. As for healthy children 
of the same age, the incidence of hospi-
talizations, MSW, any wheezing, LRTI, fe-
ver, and myalgia was similar in LAIV- and 
TIV-vaccinated children. Regarding other 
reactogenicity endpoints, the only signif-
icant difference was observed for rhinitis/
blocked nose, which affected up to ~68% 
of children after LAIV and up to ~53% of 
children after TIV, depending on vaccine 
dose and study (percentages estimated 
from graphical presentation in [16]).
Fleming et al. [15] investigated LAIV 
and TIV in children and adolescents 
6–17 years of age with a clinical diagno-
sis of asthma. Wheezing (reported with-
in 15 days after vaccination) occurred sig-
nificantly more often after TIV than af-
ter LAIV (23.8% vs. 19.5% of vaccinees, 
p=0.02); MSW and LRTI are not report-
ed as separate endpoints. Frequencies of 
asthma exacerbations, unscheduled clinic 
visits, and hospitalizations in the 42 days 
after vaccination are displayed as a bar 
chart only, showing very similar inci-
dences after LAIV and TIV (~12%, ~8%, 
and <0.5%). Fever and myalgia (reported 
within 15 days after vaccination) occurred 
with similar frequencies after LAIV and 
TIV.
Ambrose et al. [11] analyzed combined 
data on safety and reactogenicity from 
the above-mentioned studies and from 
placebo- controlled trials of LAIV. Their 
analysis shows that a runny or blocked 
nose is reported significantly more often 
after LAIV than after TIV, likely result-
ing from the nasal application of LAIV. 
Headache and decreased activity or tired-
ness were reported significantly more of-
ten after LAIV than after placebo. The in-
cidence of local reactions to the intramus-
cular injection of TIV (redness, swelling, 
pain at the injection site) is not reported in 
this publication.
Data on adverse events following im-
munization from the US, where LAIV 
has been licensed since 2003, have not 
generated any safety signals, neither in 
the passive Vaccine Adverse Event Re-
porting System (VAERS), nor in a post-
marketing study including approximate-
ly 28,000 children vaccinated with LAIV 
[17].
Quality of the evidence
The detailed appraisal of the quality of 
the available evidence according to the 
GRADE framework (i.e., the confidence 










































































is presented in the GRADE evidence pro-
files (. Tab. 3, 4).
Efficacy
The quality of the evidence for a superi-
or efficacy of LAIV (compared to TIV) 
against the outcomes ‘laboratory-con-
firmed influenza’ and ‘lower respiratory 
tract disease’ in children aged 2–6 years 
is considered ‘high’. Evidence quality re-
garding the outcome ‘hospitalization’ is 
considered ‘moderate’ due to imprecision 
caused by the low number of cases. Ac-
cording to GRADE, the overall quality of 
the evidence regarding vaccine efficacy is 
therefore considered ‘moderate’ for chil-
dren aged 2–6 years. For the age group 
7–17 years, overall evidence regarding ef-
ficacy is considered ‘low’, since evidence 
quality for the critical outcome ‘hospital-
ization’ is considered ‘low’ due to very se-
rious imprecision of the effect estimate, 
which is compatible with considerable 
benefit and harm. No evidence is avail-
able regarding efficacy against the out-
come ‘death’ in either age group.
Safety
The available data suggest no safety con-
cerns regarding LAIV in comparison to 
TIV in children and adolescents aged 
≥2 years. However, cases of ‘medically sig-
nificant wheezing’ and ‘hospitalization’—
outcomes ranked as critical by STIKO—
occurred infrequently, resulting in inci-
dence estimates with wide confidence 
intervals including the value ‘1’, mean-
ing that the estimates are imprecise and 
compatible with both a higher or lower 
incidence after LAIV in comparison to 
TIV. Therefore, STIKO judged the over-
all quality of the evidence regarding safe-
ty of LAIV relative to TIV as ‘moderate’.
Discussion
For children aged ≤6 years, two random-
ized head-to-head studies of LAIV vs. TIV 
[13, 14], conducted in different seasons, 
demonstrated that LAIV conferred bet-
ter protection against influenza than TIV. 
The observed relative efficacy of LAIV 
vs. TIV was very similar in both studies, 
51% and 54%, respectively (. Fig. 2a). 
For older children and adolescents aged 
7–17 years, the advantage of LAIV was 
considerably smaller, only marginally sta-
tistically significant [relative efficacy 32% 
(95% CI: 3%–52%), . Fig. 2b] and based 
on evidence from one study in one influ-
enza season only [15].
An important question STIKO sought 
to answer is up to what age LAIV confers 
better protection against influenza than 
TIV. In adults, several studies have shown 
that LAIV provides worse protection than 
TIV against laboratory-confirmed influ-
enza (see meta-analysis by Belshe et al. 
[9]). This was also observed in a random-
ized study comparing LAIV, TIV, and pla-
cebo in very young adults with a mean 
age of 23.3 years (range 18–49 years) [18]. 
Compared to placebo, vaccine efficacy 
against laboratory-confirmed influenza 
was higher for TIV than for LAIV (68% 
vs. 36%), resulting in a significantly better 
relative efficacy of TIV vs. LAIV of 50% 
(95% CI: 20%–69%).
In summary, the results suggest that 
the age up to which LAIV provides bet-
ter protection than TIV lies between 7 and 
about 18 years. Further specification is not 
possible on the basis of available data. Im-
munologically, it appears plausible that 
protection provided by LAIV decreases 
with increasing age and recurrent natural 
interaction of the vaccinee with influenza 
viruses. As observed with other live vac-
cines, the attenuated viruses contained in 
LAIV may be rapidly inactivated in vac-
cinees with established partial influenza-
specific immunity [5].
Regarding the safety of LAIV, increased 
rates of medically significant wheez-
ing and hospitalization were observed in 
children aged <24 months after vaccina-
tion with LAIV [14]. As a consequence, 
Fluenz® was licensed only for individu-
als aged at least 2 years. There is no evi-
dence to date for safety concerns regard-
0.1 1 10
Study RR (95% CI) Relative vaccine
ecacy (%)
Ashkenazi et al. (2006)
Belshe et al. (2007)
0.49 (0.32 - 0.76) 51 (24 - 68)
54 (45 - 62)0.46 (0.38 - 0.55)






Study RR (95% CI) Relative vaccine
ecacy (%)
Fleming et al. (2006)
Overall
0.68 (0.48 - 0.97) 32 (3 - 52)







Children 6 months to 6 years of age








































































































































































































































































































        – – – –   CRITI-
CAL
aIn both studies, children <2 years of age are included, but subgroup analyses revealed no major impact on overall VE: pooled RR excluding children <2 years was 0.47 
(95%CI: 0.38–0.58) [12]. bPooled RR has wide CI including benefit and harm. cData are based on surveillance days. dAE adverse event. eRR has wide CI including benefit and 














































































































































































































































        – – – –   CRITI-
CAL
aPooled RR has very wide CI including large benefit and severe harm. bData are based on surveillance days. cAE adverse event. dRR has wide CI including benefit and harm.
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ing healthy children and children with 
well-controlled asthma in the licensed age 
range from 2 to 17 years. However, the size 
of currently available studies is not suffi-
cient to detect rare adverse events. More-
over, precautions are expressed for the use 
of LAIV in children with significant ob-
structive lung disease. Non-standardized 
reporting of safety endpoints hampered 
pooled analysis of safety data from differ-
ent studies.
The three comparative trials of LAIV 
and TIV included healthy children as well 
as children with a history of respiratory 
infections or asthma. For other groups of 
children for whom STIKO recommends 
annual influenza vaccination, e.g., with 
chronic cardiovascular, neurological, liver, 
or kidney diseases and diabetes, no specif-
ic data are available. Children with “seri-
ous chronic disease (including progressive 
neurologic disease)” were excluded from 
studies [13] and [15], although this is not 
mentioned as an exclusion criterion in the 
study [14]. It seems plausible that the find-
ings on efficacy and safety of LAIV also 
apply to these patient groups, who can be 
considered immunocompetent. For an-
other important target group for influen-
za vaccination, namely children with im-
munocompromising conditions, LAIV is 
contraindicated.
STIKO concluded in view of the avail-
able evidence that a preferential recom-
mendation of LAIV is warranted for chil-
dren aged 2–6 years, but not for older chil-
dren. It should be noted that in the US, un-
like in the EU, LAIV is licensed from age 
2 to 49 years; however, there is no prefer-
ential recommendation of either LAIV or 
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